Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03711825
Other study ID # LYN-057-C-002
Secondary ID ACTRN12618001426
Status Completed
Phase Early Phase 1
First received
Last updated
Start date September 10, 2018
Est. completion date November 13, 2018

Study information

Verified date February 2019
Source Lyndra Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess how long memantine hydrochloride (HCl) (50 mg) extended release capsules stay in the stomach as determined by imaging assessment (MRI or abdominal ultrasound).

To evaluate the safety of a memantine HCl extended release capsule formulation


Description:

This is a single centre, open label, single dose study in healthy adult subjects.

Eligible individuals will be admitted to an inpatient unit in two or more cohorts. Enough eligible individuals will be admitted allowing for the enrollment of the Sentinel (n= 2) and Main Group (total of n=8 in Main), and an optional Supplemental Group (n= 6), if required.

All enrolled subjects will be dosed with a single administration of an extended release capsule containing memantine hydrochloride (LYN-057), 50 mg. Dosing will be conducted in an inpatient clinical unit, with access to an acute care facility. Subjects will remain in the inpatient unit for 7 days after dosing. During this time, subjects will undergo intermittent imaging assessments for gastric retention [magnetic resonance imaging (MRI) and abdominal ultrasound (U/S)], safety assessments, blood sampling for evaluation of memantine pharmacokinetics (PK), and faecal collections for assessments of formulation components and bowel movement characteristics.

Subjects will return to the clinic for PK sampling and safety assessments on Days 10, 15, 22 and Day 29 (End of Study Visit). In addition, some subjects may continue to perform faecal collection and/or may undergo imaging assessments on Day 10 based on clinical criteria. On Day 29 (End of Study Visit), subjects will undergo final safety and PK assessments and will be discharged from the study.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date November 13, 2018
Est. primary completion date October 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria:

1. Healthy male and female subjects

2. Body mass index of 18.0 to 30.0 kg/meters-squared

3. Suitable scores for two swallowing questionnaires

4. Demonstrate normal swallowing and gastrointestinal passage for capsule, as assessed while undergoing imaging studies

5. Must provide written informed consent

Exclusion Criteria:

1. Participants who have previously been enrolled in this study

2. History of any drug or alcohol abuse in the past 2 years

3. Current smokers and those who have smoked within the past 12 months

4. Individuals with clinically significant medical history relating to the gastrointestinal tract and potential complications, thereof

5. Individuals with a positive test for HIV, hepatitis B or hepatitis C

6. Individuals who are contraindicated based on memantine HCl

7. Serious adverse reaction or serious hypersensitivity to components of the study formulation or patency capsule

8. Individuals who have received any experimental agent within 30 days (or 5 half-lives), whichever is longer, prior to the date of dosing

9. Individuals with contraindication to MRI imaging

10. Individuals with functional constipation, irritable bowel, or functional diarrhea, as evaluated by standardized questionnaire

11. Individuals with contraindications to elective X-ray based on known or expected radiation exposure

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LYN-057
Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
Procedure:
Imaging Assessment (MRI)
Imaging assessments [MRI] will be performed on specified days according to protocol
Imaging Assessment (U/S)
Imaging assessments (abdominal U/S) will be performed on specified days according to protocol

Locations

Country Name City State
Australia CMAX Adelaide South Australia

Sponsors (1)

Lead Sponsor Collaborator
Lyndra Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Gastric retention by imaging assessment by MRI Visualization of formulation/formulation components in stomach by MRI Up to 9 days post-dosing
Primary Gastric retention by imaging assessment by abdominal U/S Visualization of formulation/formulation components in stomach by abdominal U/S Up to 9 days post-dosing
Primary Safety and tolerability of a single dose of LYN-057 extended release capsule Safety collected from a combination of the following: Adverse Event (AE) reporting and examinations specified per protocol Through study completion, up to 3 months
Secondary Memantine HCl pharmacokinetics - Maximum Plasma Concentration (Cmax) Memantine HCl pharmacokinetics - Cmax by validated assay Pre-dose, on day of dosing at 2, 4, 6, 8 and 12 hours post-dosing, thereafter daily during inpatient stay through Day 8. After Day 8, PK sampling on Day 10, 15, 22 and 29.
Secondary Memantine HCl pharmacokinetics - Time after administration of maximum plasma concentration (Tmax) Memantine HCl pharmacokinetics - Tmax by validated assay Pre-dose, on day of dosing at 2, 4, 6, 8 and 12 hours post-dosing, thereafter daily during inpatient stay through Day 8. After Day 8, PK sampling on Day 10, 15, 22 and 29.
Secondary Memantine HCl pharmacokinetics - Area Under the Curve (AUC) Memantine HCl pharmacokinetics - AUC by validated assay Pre-dose, on day of dosing at 2, 4, 6, 8 and 12 hours post-dosing, thereafter daily during inpatient stay through Day 8. After Day 8, PK sampling on Day 10, 15, 22 and 29.
Secondary Physical features of recovered formulation components Recording of the descriptive physical features, e.g. number of polymeric arms (if separate) or attached to the core, of formulation components recovered from collected fecal specimens Through study completion, up to 29 days
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1